Likewise, in a colorectal cancer model partially sensitive to chemoimmunotherapy, COX-2 inhibition further improved tumour control, indicating that pharmacologically targeting the COX-2/PGE2 pathway could benefit tumours both sensitive or refractory to chemoimmunotherapy. This evidence concerns the gene PTGS2 and neoplasm.